Clinical Trial Update: Testing VS-6063 (Defactinib) as a Potential Targeted Treatment in Cancers With NF2 Genetic Changes (MATCH-Subprotocol U) [Phase 2]

View source ↗

Summary

Phase 2 MATCH subprotocol U update on defactinib (VS-6063) for cancers with NF2 genetic changes, with results posted and the trial listed as active but not recr…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hematologic Malignancy
• Lymphoma
• Multiple Myeloma
• Solid Tumor

Drugs mentioned

• defactinib (VS-6063) (defactinib)

Snippet

Sponsor: National Cancer Institute (NCI) | Conditions: Advanced Lymphoma, Advanced Malignant Solid Neoplasm | Phase 2 | Status: ACTIVE_NOT_RECRUITING | Results posted: 2025-04-08